Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Ubrogepant (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Registrational; Therapeutic Use
- Acronyms ACHIEVE II
- Sponsors Allergan
- 26 Apr 2022 Results of pooled analysis from ACHIEVE I and ACHIEVE II trials demonstrating therapeutic benefit at 1-Hour post-dose presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 07 Dec 2021 Results of post hoc pooled analysis, assessing efficacy endpoints from ACHIEVE I and ACHIEVE II (n=2247) and safety outcomes from NCT02873221 (n=813); published in the Advances in Therapy
- 18 Aug 2021 Results of an analysis from four clinical trials: SAMURAI, ACHEIVE III, SPARTAN and NCT02873221 assessing use of placebo followed by placebo in randomized trials and its ethical standpoint published in the Cephalalgia